Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 47: 946-948, 2001;
This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ikemoto, M.
Right arrow Articles by Totani, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ikemoto, M.
Right arrow Articles by Totani, M.
Related Collections
Right arrow Animal Clinical Chemistry
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2001;47:946-948.)
© 2001 American Association for Clinical Chemistry, Inc.


Technical Briefs

Liver-Type Arginase Is a Highly Sensitive Marker for Hepatocellular Damage in Rats

Masaki Ikemoto1a, Shoji Tsunekawa2, Yoshinobu Toda3 and Masayuki Totani4

1 College of Medical Technology, Kyoto University, Kyoto 606-8507, Japan

2 Department of Surgery, NTT West Kyoto Hospital, Kyoto 601-8441, Japan

3 Study Center for Human Remains, Faculty of Medicine, Kyoto University, Kyoto 606-8507, Japan

4 The National Institute of Health and Nutrition, Shinjuku-ku, Tokyo 162-8636, Japan

aauthor for correspondence: fax 81-75-751-3945, e-mail mmas{at}kuhp.kyoto-u.ac.jp

Hepatic enzymes in serum, such as aspartate aminotransferase (AST) and alanine aminotransferase (ALT), are routinely measured in serum for the diagnosis of hepatic disease; however, these enzymes are not liver specific because they are widely distributed in nonhepatic tissues. In contrast, urea cycle enzymes, i.e., liver-type arginase (ARG), ornithine carbamoyltransferase (OCT), and argininosuccinate synthase (AS), exist almost exclusively in the liver (1)(2)(3) and may serve as more specific markers of liver injury. It has been reported that some of the urea cycle enzymes leak rapidly from hepatocytes when liver cells are damaged (4)(5)(6)(7)(8)(9)(10)(11). Although there are several "hepatic marker" enzymes, including the urea cycle enzymes, it is not known which one of them is the most suitable enzyme for early detection of hepatocellular injury. To confirm the most suitable enzyme for this purpose, it is important to verify changes in the serum concentrations of urea cycle enzymes after liver damage, in comparison with enzymes in routine use. Two rat experimental models were designed: (a) a chemical liver injury model induced by carbon tetrachloride, and (b) an ischemia-reperfusion liver injury model. We measured the urea cycle enzymes ARG, OCT, and AS in sera, using procedures that we described previously (9)(12). Anti-OCT and AS IgGs were conjugated with N-hydroxysuccimidobiotin, essentially as described by Akhoundi et al. (13). These conjugates were used as second antibodies. Evaluation was based on the limited localization of the urea cycle enzymes in hepatocytes and the high specificity of our antibody. Serum activities of AST and ALT were measured by an automated blood chemistry analyzer (Hitachi 736-60E).

Chemical liver injury was induced by intraperitoneal injection of carbon tetrachloride in 4-week-old male Wistar rats (n = 14). The rats were anesthetized with ether and killed at time points 0 (before treatment; control), 15 min, 30 min, 45 min, 1 h, 3 h, and 5 h for the short-interval experiments (two rats at each time point). Blood samples were collected and incubated for 1 h at 37 °C; the serum was then separated. In the ischemia-reperfusion injury model, 5-week-old male Wistar rats (n = 10) were used. Each rat was anesthetized with ether, and total liver ischemia was determined by clamping the hepatoduodenal ligament, which contains the hepatic artery and portal vein, for 30 min using a small clamp unit; thereafter, the liver was reperfused by declamping the ligament. At time points 0 (before treatment), 5 min, 10 min, 20 min, and 30 min after reperfusion of the liver, blood samples were drawn quickly from the inferior vena cava; serum samples were then separated as described above.

We measured three urea cycle enzymes (liver-type ARG, OCT, and AS) and two conventional hepatic markers (AST and ALT) in the sera of rats after intraperitoneal injection of carbon tetrachloride. We then compared the patterns of increase and fluctuations of AST and ALT >5 h after treatment with the chemical agent. Serum liver-type ARG increased dramatically immediately after the injection, and within 30 min, it was ~45-fold higher than the concentration before treatment (Fig. 1A ). In comparison with ARG, the concentrations of all other hepatic markers tested in this study remained low and were, at most, ~10-fold higher than before treatment. In every case, the liver-type ARG increased more on a relative basis than any of the other hepatic enzymes. An ischemia-reperfusion liver injury model was designed to confirm the leak-prone character of liver-type ARG. After reperfusion, we measured serum liver-type ARG and determined the activities of AST and ALT. A large amount of liver-type ARG leaked immediately into the blood stream ~5 min after the reperfusion. The concentration was 60-fold higher than before treatment and gradually increased thereafter (Fig. 1B ). Thirty minutes after the reperfusion, the ARG concentration was 100-fold higher than the control concentration, whereas the serum AST and ALT concentrations were never >10-fold higher than in the controls throughout the course of the experiment. It has been reported that AST and ALT increase dramatically in acute liver congestion or acute occlusion of the hepatic artery (4). In our study, the increase of liver-type ARG was more rapid than increases in AST or ALT, indicating a potential clinical usefulness of ARG as a hepatic marker.



View larger version (36K):
[in this window]
[in a new window]
 
Figure 1. Changes in serum liver-type ARG, OCT, AS, and other hepatic enzymes in rats with liver damage induced by carbon tetrachloride during a short period after the injection of carbon tetrachloride (A) and after the reperfusion of ischemic liver (B).

(A), 14 rats received carbon tetrachloride intraperitoneally (~0.6 mL/250 g of body weight; n = 14). At time point 0 (before treatment) and at 15 min, 30 min, 45 min, 1 h, 3 h, and 5 h, two animals were killed and examined for serum concentrations of ARG, OCT, AS, and other hepatic enzymes (AST and ALT). We measured ARG with our previously reported ELISA method (12), and the activities of the other hepatic enzymes were determined spectrophotometrically. Reference values were the means of two rats in the control group at time 0 (ARG, 3.5 µg/L; AS, 4.7 µg/L; OCT, 5.1 µg/L; AST, 144 U/L; ALT, 55 U/L). Y axis represents amounts or activities of the enzymes relative to their reference values. (B), before treatment, liver ischemia was induced in 10 rats for 30 min. Blood samples were obtained from each rat at time point 0 (before treatment) and ~5 min, 10 min, 20 min, and 30 min after reperfusion of the liver. The concentrations of ARG, AST, and ALT were determined as described. Assay conditions and symbols are the same as for A. Reference values were the means of two rats from the control group at time point 0 (ARG, 5.0 µg/L; AST, 203 U/L; ALT, 51 U/L). Y axis represents amounts or activities of the enzymes relative to their reference values. Bars indicate the ranges for the duplicate determinations of each sample.

We previously described the potential importance of measuring human serum liver-type ARG in diagnosis of hepatic disorders (9). However, a lack of knowledge about the turnover of ARG has hampered a wider application of this enzyme for clinical diagnosis. As shown in Fig. 1Up , our results indicate that liver-type ARG is increased substantially in the acute phase of liver disorders.

We suggest that after induction of liver damage with carbon tetrachloride and ischemia-reperfusion injury, liver-type ARG, in comparison with the other enzymes tested in this study, leaks most profusely into the blood from the damaged liver. In an immunohistochemical study (data not shown), massive disappearance of liver-type ARG from hepatocytes immediately after liver damage was demonstrated. This further supports our hypothesis that liver-type ARG is an enzyme that reflects damage to hepatocytes regardless of the cause. The release of liver-type ARG into the bloodstream appears to differ from the release of AST and ALT (Fig. 1Up ), supporting the leak-prone character of ARG.

ALT and AST are markers of liver cytolysis (4)(14)(15). During a short period after the injection of the chemical agent, liver-type ARG increased more rapidly than ALT (Fig. 1Up ), indicating that the clinical value of the enzyme could be equal or superior to that of ALT, which supports an earlier study indicating that after partial hepatectomy, liver-type ARG increased more dramatically than ALT and AST (5).

OCT leaks out of hepatocytes into the bloodstream through the mitochondrial and plasma membranes, whereas ALT, which is a cytosolic enzyme, and liver-type ARG leak only through the plasma membrane. The difference in the pattern of increase of ARG compared with OCT and the transaminases may be attributable to their differential localization in hepatocytes, as well as the fact that liver-type ARG has a smaller molecular mass than other hepatic-marker enzymes (13)(16).

Our results indicate that among the hepatic enzymes tested in the present study, the release of liver-type ARG may be unique, particularly in the acute phase of hepatocellular injury, and that the measurement of ARG has its own clinical merit for detecting hepatic lesions.


Acknowledgments

This work was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan (to M.I.). We thank Kiyoyuki Takahashi of Kyoto University for technical instruction and helpful advice for immunohistochemical staining.


References

  1. Boric O, Straus B. Separation of arginase from human tissues by agar gel electrophoresis. J Clin Chem Clin Biochem 1976;1:533-535.
  2. Cabello J, Prajoua V, Plaza M. Immunodiffusion studies on human liver and erythrocytes. Biochem Biophys Acta 1965;105:583-593.[Medline] [Order article via Infotrieve]
  3. Zamecka E, Porembska Z. Five forms of arginase in human tissues. Biochem Med Metab Biol 1988;39:258-266.[Web of Science][Medline] [Order article via Infotrieve]
  4. Schmidt E, Schmidt FW. Enzyme diagnosis in diseases of the liver and the biliary system. Adv Clin Enzymol 1979;1:239-292.
  5. Panis Y, McMullan M, Emond JC. Progressive necrosis after hepatectomy and the pathophysiology of liver failure after massive resection. Surgery 1997;121:142-149.[Web of Science][Medline] [Order article via Infotrieve]
  6. Yu Y, Terada K, Nagasaki A, Takiguchi M, Mori M. Preparation of recombinant argininosuccinate synthetase and argininosuccinate lyase: expression of the enzymes in rat tissues. J Biochem 1995;117:952-957.[Abstract/Free Full Text]
  7. Saheki T, Komorizono K, Miura T, Ichiki H, Yagi Y, Hashimoto S. Clearance of arginino-succinate synthetase from the circulation in acute liver diseases. Clin Biochem 1989;23:139-141.
  8. Miura T, Ichiki H, Saheki T, Yagi Y, Kobayashi K, Komorizono K, et al. Serum argininosuccinate synthetase as a specific marker for liver diseases. Clin Chem Enzymol Commun 1989;1:153-157.
  9. Ikemoto M, Ishida A, Tsunekawa S, Ozawa K, Kasai Y, Totani M, Ueda K. Development of a new ELISA system for human liver-type arginase and its potential clinical application. Clin Chem 1993;39:794-799.[Abstract/Free Full Text]
  10. Ikemoto M, Tsunekawa S, Tanaka K, Tanaka A, Yamaoka Y, Ozawa K, et al. Liver-type arginase in serum during and after liver transplantation: a novel index in monitoring conditions of the liver graft and its clinical significance. Clin Chim Acta 1998;271:11-23.[Web of Science][Medline] [Order article via Infotrieve]
  11. Ozaki M, Terada K, Kanazawa M, Fujiyama S, Tomita K, Mori M. Enzyme-linked immunosorbent assay of carbamoylphosphate synthetase I: plasma enzyme in rat experimental hepatitis and its clearance. Enzyme Protein 1995;48:213-221.
  12. Ikemoto M, Tabata M, Miyake T, Kono T, Mori M, Totani M, Murachi T. Expression of human liver arginase in Escherichia coli. Purification and properties of the product. Biochem J 1990;270:697-703.[Web of Science][Medline] [Order article via Infotrieve]
  13. Akhoundi C, Rochet N, Ferrua B, Rossi B. Production and characterization of monoclonal and polyclonal antibodies to human {alpha} 2-HS: development of a two-site ELISA test. J Immunol Methods 1994;172:189-196.[Web of Science][Medline] [Order article via Infotrieve]
  14. Wada H, Snell EE. Enzymatic transamination of pyridoxamine. II. Crystalline pyridoxamine-pyruvate transaminase. J Biol Chem 1962;237:133-137.[Free Full Text]
  15. Ishiguro M, Takio K, Suzuki M, Oyama R, Matsuzawa T, Titani K. Complete amino acid sequence of human liver cytosolic alanine aminotransferase (GPT) determined by a combination of conventional and mass spectral methods. Biochemistry 1991;30:10451-10457.[Medline] [Order article via Infotrieve]
  16. Watanabe Y, Mori S, Fujiyama S, Sato T, Mori M. Clinical evaluation of serum ornithine carbomoyltransferase by enzyme-linked immunosorbent assay in patients with liver diseases. Enzyme Protein 1994;48:18-26.[Web of Science][Medline] [Order article via Infotrieve]



The following articles in journals at HighWire Press have cited this article:


Home page
J. Pharmacol. Exp. Ther.Home page
B. A. Merrick, M. E. Bruno, J. H. Madenspacher, B. A. Wetmore, J. Foley, R. Pieper, M. Zhao, A. J. Makusky, A. M. McGrath, J. X. Zhou, et al.
Alterations in the Rat Serum Proteome during Liver Injury from Acetaminophen Exposure
J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 792 - 802.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (8)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ikemoto, M.
Right arrow Articles by Totani, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ikemoto, M.
Right arrow Articles by Totani, M.
Related Collections
Right arrow Animal Clinical Chemistry
Right arrow Proteomics and Protein Markers


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS